Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05957081




Registration number
NCT05957081
Ethics application status
Date submitted
26/05/2023
Date registered
24/07/2023
Date last updated
18/11/2023

Titles & IDs
Public title
Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309
Scientific title
A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors
Secondary ID [1] 0 0
KEYNOTE-E80
Secondary ID [2] 0 0
MarkV-01
Universal Trial Number (UTN)
Trial acronym
MarkV-01
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced or Metastatic Solid Tumors 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PMC-309 monotherapy
Treatment: Drugs - PMC-309 Dose Escalation in Combination with Pembrolizumab
Treatment: Drugs - PMC-309 Dose Expansion

Experimental: Phase 1 a: Part A: PMC-309 Monotherapy Dose Escalation - Phase 1a will enroll participants with advanced or metastatic solid tumors to assess safety, tolerability, PK and clinical efficacy in response to treatment with PMC-309 as a monotherapy
Dosage form and Route of administration: The duration of a treatment cycle is 3 weeks/21 days. Participants will be administered a weekly dose of PMC-309 per cycle as follows:
Cycle Week 1/Day 1
Cycle Week 2/Day 8 ± 2 days
Cycle Week 3/Day 15 ± 2 days PMC-309 will be administered intravenously over 1 hour (± 0.5 hours), after which participants will be observed for a period of 1.5 hours post administration.

Experimental: Phase 1a: Part B: PMC-309 Dose Escalation in Combination with Pembrolizumab - Part B will establish the MTD/preliminary RP2D of PMC-309 when administered in combination with 200 mg pembrolizumab. Part B will be conducted after completion of Part A (PMC-309 monotherapy dose escalation) and before the commencement of Phase 1b.
Dosage form and Route of administration: The duration of a treatment cycle is 3 weeks/21 days. Participants will be administered a weekly dose of PMC-309 plus one dose of pembrolizumab at 200 mg per cycle as follows:
Cycle Week 1/Day 1: pembrolizumab (administered first), followed by administration of PMC-309.
Cycle Week 2/Day 8 ± 2 days: PMC-309 only
Cycle Week 3/Day 15 ± 2 days: PMC-309 only. Both PMC-309 and pembrolizumab will be administered intravenously.

Experimental: Phase 1b: Dose Expansion - Phase 1b will enroll participants after completion of DLT assessments for Phase 1a.
Phase 1b will enroll participants with advanced or metastatic tumor types into 1 of 2 cohorts to assess response of monotherapy of PMC-309 and response of PMC-309 in combination with pembrolizumab.
Cohort A: PMC-309 monotherapy therapy
- PMC-309 dosing will be at the preliminary RP2D, as identified in Phase 1a: Part A
Cohort B: PMC-309 plus pembrolizumab combination therapy - PMC-309 dosing will be as identified in Phase 1a: Part B in combination with 200 mg pembrolizumab Participants will be randomly assigned to Cohort A or Cohort B until 20 participants are enrolled in each cohort.


Treatment: Drugs: PMC-309 monotherapy
PMC-309 will be administered intravenously.

Treatment: Drugs: PMC-309 Dose Escalation in Combination with Pembrolizumab
Both PMC-309 and pembrolizumab will be administered intravenously. At the time of the combination therapy (Week 1/Day 1 of each cycle), participants will be dosed with pembrolizumab first, administered over 0.5 hours (± 10 minutes). Following an interval of 1 hour (± 15 minutes), participants will be dosed with PMC-309 administered over 1 hour (± 0.5 hours), after which participants will be observed for a period of 1.5 hours post administration.

Treatment: Drugs: PMC-309 Dose Expansion
Phase 1b will enroll participants with advanced or metastatic tumor types into 1 of 2 cohorts:
Cohort A: PMC-309 monotherapy therapy
- PMC-309 dosing will be at the preliminary RP2D, as identified in Phase 1a: Part A
Cohort B: PMC-309 plus pembrolizumab combination therapy - PMC-309 dosing will be as identified in Phase 1a: Part B in combination with 200 mg pembrolizumab
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants with abnormal vital signs in response ot treatment with PMC- 309
Timepoint [1] 0 0
Phase 1a and 1b- Upto 35 Cycles (each cycle is 21 days)
Primary outcome [2] 0 0
Number of participants with abnomal clinically significant results with physical examination in response to the treatment with PMC-309
Timepoint [2] 0 0
Phase 1a and 1b- Upto 35 Cycles (each cycle is 21 days)
Primary outcome [3] 0 0
Number of participants with abnormal clinically significant 12-lead electrocardiogram (ECG) parameters in response to treatment with PMC-309
Timepoint [3] 0 0
Phase 1a and 1b- Upto 35 Cycles (each cycle is 21 days)
Primary outcome [4] 0 0
Number of participants with abnormal clinically significant laboratory results in response to treatment with PMC-309
Timepoint [4] 0 0
Phase 1a and 1b- Upto 35 Cycles (each cycle is 21 days)
Primary outcome [5] 0 0
Number of participants with adverse events receiving treatment with PMC-309
Timepoint [5] 0 0
Phase 1a and 1b- Upto 35 Cycles (each cycle is 21 days)
Primary outcome [6] 0 0
Number of participants with abnormal changes in Eastern Cooperative Oncology Group (ECOG) performance status.
Timepoint [6] 0 0
Phase 1a and 1b- Screening
Primary outcome [7] 0 0
Number of participants with abnormal changes in Eastern Cooperative Oncology Group (ECOG) performance status.
Timepoint [7] 0 0
Day1 of every cycle (each cycle is 21 days)
Primary outcome [8] 0 0
To determine the maximum tolerated dose (MTD) of PMC-309 monotherapy (Part A) and establish the preliminary RP2D of PMC-309.
Timepoint [8] 0 0
Upto 21 days
Primary outcome [9] 0 0
To determine the MTD and establish the preliminary RP2D of PMC-309 when administered in combination with pembrolizumab at 200 mg (Part B).
Timepoint [9] 0 0
Upto 21 Days
Secondary outcome [1] 0 0
To assess the clinical efficacy of PMC-309 in the treatment of advanced or metastatic solid tumors by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Timepoint [1] 0 0
Upto 35 Cycles (each cycle is 21 days)
Secondary outcome [2] 0 0
The plasma pharmacokinetic endpoints of the study is assessed by peak serum concentration (Cmax)
Timepoint [2] 0 0
Upto 35 Cycles (each cycle is 21 Days)
Secondary outcome [3] 0 0
The plasma pharmacokinetic endpoints of the study is assessed by time to peak plasma concentration (Tmax)
Timepoint [3] 0 0
Upto 35 Cycles (each cycle is 21 Days)
Secondary outcome [4] 0 0
PK parameter assessed by serum concentration at specified timepoints for area under curve (AUC)
Timepoint [4] 0 0
Upto 35 Cycles (each cycle is 21 Days)
Secondary outcome [5] 0 0
To assess the clinical efficacy of PMC-309 at the RP2D as a monotherapy and in combination with pembrolizumab
Timepoint [5] 0 0
Upto 35 Cycles (each cycle is 21 Days)
Secondary outcome [6] 0 0
PK parameter assessed by serum concentration over time of PMC-309 at the RP2D as a monotherapy and in combination with pembrolizumab.
Timepoint [6] 0 0
Upto 35 Cycles (each cycle is 21 Days)

Eligibility
Key inclusion criteria
To be eligible for this study, a participant must meet ALL of the following inclusion
criteria:

1. The participant voluntarily signs an informed consent form (ICF) indicating they
understand the purpose and procedures required for the study and are willing to
participate in the study.

2. Are at least 18 years of age.

3. Are diagnosed with advanced or metastatic solid tumors (non-lymphoma) by histology or
pathology that is metastatic or unresectable and considered relapsed and/or refractory
to prior therapy.

Definition of anti-PD-1/L1 refractory participant:

Participants must have progressed on treatment with an anti-PD1/L1 mAb administered
either as monotherapy, or in combination with other checkpoint inhibitors or other
therapies. PD-1 treatment progression is defined by meeting all of the following
criteria:

1. Has received at least 2 doses of an approved anti-PD-1/L1 mAb.

2. Has demonstrated disease progression (PD) after PD-1/L1 as defined by RECIST
v1.1. The initial evidence of PD is to be confirmed by a second assessment no
less than 4 weeks from the date of the first documented PD, in the absence of
rapid clinical progression.

3. PD has been documented within 12 weeks from the last dose of anti-PD-1/L1 mAb.

i. PD is determined according to iRECIST v1.1. ii. This determination is made by the
PI (or designee). Once PD is confirmed, the initial date of PD documentation will be
considered the date of disease progression

4. Have measurable disease per RECIST v1.1 documented by computerized tomography scan (CT
scan) and/or magnetic resonance imaging (MRI), measurable at Baseline. Lesions
situated in a previously irradiated area are considered measurable if progression has
been demonstrated in such lesions.

5. Have an ECOG performance status of 0 or 1.

6. Can satisfy the following criteria in hematologic, renal, and hepatic function tests
performed within 7 days prior to screening:

1. Hematologic tests:

- ANC more than and equal to 1.5 × 109 per L.

- Platelets more than and equal to 100 × 109 per L.

- Hemoglobin more than and equal to 9.0 g per dL or more than and equal to 5.6
mmol per L.

Note: Criteria must be met without packed red blood cell (pRBC) transfusion
within the prior 2 weeks. Participants can be on a stable dose of erythropoietin
(more than equal to approximately 3 months).

2. Blood coagulation tests:

- Prothrombin time less than and equal to 1.5 × upper limit of normal (ULN).

- Activated partial thromboplastin time less than and equal to 1.5 × ULN.

3. Hepatic function tests:

- Total bilirubin less than and equal to 1.5 × ULN or direct bilirubin less
than and equal to ULN for participants with total bilirubin levels more than
and equal to 1.5 × ULN.

- Aspartate aminotransferase or alanine aminotransferase less than and equal
to 2.5 × ULN (less than and equal to 5× ULN in case of liver metastasis).

4. Renal function test:

- less than and equal to 1.5 × ULN or creatinine clearance more than and equal
to 30 mL/min for participant with creatinine levels above 1.5 ×
institutional ULN.

7. Are willing and able to adhere to the prohibitions and restrictions as specified in
the study protocol.

8. Eligible participants (male and female) of childbearing potential must agree to use
reliable contraception (hormone, barrier method, or abstinence) from Screening (Day
-1) until at least 120 days after administration of the last dose of the IP.

9. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test at
Screening (Day -1) and be willing to have additional pregnancy tests as required
throughout the study.

10. Human immunodeficiency virus (HIV) infected participants must be on anti-retroviral
therapy (ART) and have a well-controlled HIV infection/disease defined as:

1. Participants on ART must have a CD4+ T-cell count 350 cells/mm3 at time of
Screening.

2. Participants on ART must have achieved and maintained virologic suppression
defined as confirmed by HIV RNA level below 50 copies/mL or the lower limit of
qualification (below the limit of detection) using the locally available assay at
the time of Screening and for at least 12 weeks prior to Screening.

3. Participants on ART must have been on a stable regimen, without changes in drugs
or dose modification, for at least 4 weeks prior to study entry (Day 1).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
A participant who meets ANY of the following exclusion criteria must be excluded from the
study:

1. Has received treatment with a VISTA targeting agent.

2. Has a history of positive testing for hepatitis B surface antigen (HBsAg) or hepatitis
C antibody (anti-hepatitis C virus) or other clinically active liver disease, or
positive testing at Screening for HBsAg or anti- hepatitis C virus.

3. HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric
Castleman Disease.

4. Has a medical condition which, in the opinion of the PI (or designee), places the
participant at an unacceptably high risk for toxicity.

5. Has a known additional malignancy that is progressing or has required active treatment
within the past 3 years.

6. Is currently participating in or has participated in a study of an investigational
agent or have received anticancer immunotherapy within 4 weeks prior to the first dose
of IP.

7. Has an active autoimmune disease with a history of flares requiring immunosuppressant
medications within the past 6 months or that has required systemic treatment in the
past 2 years (ie, with use of disease modifying agents, corticosteroids or
immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic
corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not
considered a form of systemic treatment and is allowed.

8. History of known or suspected seizure disorder.

9. Has oxygen-dependent chronic disease.

10. Serious Grade 4 venous thromboembolic event including pulmonary embolism.

11. Participant is receiving therapeutic anticoagulants.

12. Has had an allogeneic tissue/solid organ transplant.

13. Major surgery (eg, requiring general anesthesia) within 4 weeks before the planned
first dose of the IP, or not fully recovered from prior surgery, or has surgery
planned during the time the participant is expected to participate in the study or
within 4 weeks after the last dose of IP.

14. Fertility exclusions:

1. Participant is pregnant, breastfeeding, or planning to become pregnant while
enrolled in this study or within 120 days after the last dose of IP; WOCBP must
have a negative pregnancy status confirmed by urine pregnancy test at Screening
and within 72 hours of first dose of the IP. (If the urine test is positive or
cannot be confirmed as negative, a serum pregnancy test will be required.)

2. Participant is a man who plans to father a child while enrolled in this study or
within 3 months after the last dose of the IP.

3. Male participants must also refrain from sperm donation during the treatment
period and for 5 terminal half-lives (of PMC-309) plus an additional 90 days (a
spermatogenesis cycle).

Note: The half-life of PMC-309 is 47 hours.

15. Vaccinated with a live vaccine within 30 days (with the exception of the annual
inactivated influenza vaccine) prior to the first dose of the IP.

16. Received COVID-19 vaccine within 7 days of the first IP administration.

17. Any medical condition for which, in the opinion of the PI or designee, participation
would not be in the best interest of the participant (eg, compromise the well-being of
the participant) or that could prevent, limit, or confound the protocol specified
assessments.

18. Uncontrolled intercurrent illness including, but not limited to, poorly controlled
hypertension; poorly controlled diabetes; ongoing active infection requiring
antibiotics or acute infectious illness (including suspected viral infection);
symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia
considered to increase risk for the participant by the PI (or designee); or active
psychiatric disorder (schizophrenia, major depressive disorder, bipolar disorder,
treated depression with ongoing antidepressant medication etc.) that would limit
compliance with study requirements.

19. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(at a dose exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior the first dose of IP.

20. Has known active central nervous system (CNS) metastases and/or carcinomatous
meningitis. Participants with previously treated brain metastases may participate
provided they are radiologically stable, (ie, without evidence of progression for at
least 4 weeks by repeat imaging [note that the repeat imaging should be performed
during Screening], clinically stable and without requirement of steroid treatment for
at least 14 days prior to first dose of IP).

21. Prior allogeneic organ or bone marrow transplant.

22. Participant has had prior therapy meeting the following:

1. Prior T-cell receptor-modified or chimeric antigen receptor T-cell (CART)
therapy.

2. Other anticancer therapy, including chemotherapy, targeted therapy, or treatment
with an investigational anticancer agent within 4 weeks prior to the first dose
of IP.

3. Has received prior radiotherapy (excluding limited palliative radiation) within 2
weeks of start of IP or has a history of radiation pneumonitis.

4. Participants must have recovered from all radiation-related toxicities and not
require corticosteroids. A 1-week washout is permitted for palliative radiation
(less than and equal to 2 weeks of radiotherapy) to non-CNS disease.

5. Except for hearing loss, alopecia and pigmentation, all toxicity caused by
previous anti-tumor therapy has recovered to Grade 1 or less.

23. Participant received prior therapy with an anti-PD-1 or anti-PD-L1 mAb or with an
agent targeting stimulatory or co-inhibitory T-cell receptors and was discontinued
from that treatment due to a Grade 3 or higher immune related AE.

24. Participant has an active autoimmune disease that required systemic treatment in the
past.

25. Has a history of (non-infectious) pneumonitis / interstitial lung disease that
required steroids or has current pneumonitis / interstitial lung disease.

26. Class III or IV heart failure by New York Heart Association (NYHA) classification.

27. History of abdominal fistula or gastrointestinal perforation within 6 months prior to
start of IP administration.

28. History of serious gastrointestinal hemorrhage within 6 months prior to start of IP
administration.

29. History of hypertensive crisis or hypertensive encephalopathy.

30. History of posterior reversible encephalopathy syndrome.

31. Social situation that would limit compliance with study requirements.

32. A diagnosis of immunodeficiency or is receiving chronic systemic corticosteroids at a
dose that exceeds 10 mg daily of prednisone equivalent or any other form of
immunosuppressive therapy within 7 days prior the first dose of the IP. Inhaled or
topical steroids are permitted in the absence of active autoimmune disease.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
28/11/2023
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
4/10/2028
Actual
Sample size
Target
67
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
Australian Hospital Care (Pindara) PTY LTD. Trading as Pindara Private Hospital - Benowa
Recruitment hospital [2] 0 0
Ballarat Regional Integrated Cancer Centre (Grampians Health) - Ballarat
Recruitment hospital [3] 0 0
Cabrini Health Limited - Malvern
Recruitment hospital [4] 0 0
Alfred Health - Melbourne
Recruitment postcode(s) [1] 0 0
4217 - Benowa
Recruitment postcode(s) [2] 0 0
3350 - Ballarat
Recruitment postcode(s) [3] 0 0
3144 - Malvern
Recruitment postcode(s) [4] 0 0
3004 - Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
PharmAbcine
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Novotech (Australia) Pty Limited
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/Industry
Name [2] 0 0
Merck Sharp & Dohme LLC
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 1a/1b, first-in-human (FIH), open label study to evaluate the safety,
tolerability, and pharmacokinetics (PK) of PMC-309, a mAb against the human VISTA ligand, in
participants with advanced or metastatic solid tumors administered as a monotherapy and in
combination with pembrolizumab.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05957081
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Andrea Tazbirkova, Dr
Address 0 0
Pindara Private Hospital
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
JinKyung Kim, Mr
Address 0 0
Country 0 0
Phone 0 0
070-4213-2925
Fax 0 0
Email 0 0
jinkyung.kim@pharmabcine.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05957081